Fig 1: Effects of abrocitinib on the JAK1/STAT1 pathway. On the 1st day after TBI, JAK1 and STAT1 showed a dramatic increase in activation. After abrocitinib treatment, the activated JAK1 and STAT1 were significantly decreased, as shown in the WB results above and can be displayed through WB (n = 5–9, one-way ANOVA with Tukey’s post-hoc test). All data are shown as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.